Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Update on Tozadenant Trial for Parkinson’s

On 11/20/17, Acorda Therapeutics, Inc. announced that it is discontinuing the tozadenant clinical trial.  They concluded that they could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.


On 11/15/17, Acorda Therapeutics, Inc. announced that several people living with Parkinson's who participated in the Phase III trial for tozadenant experienced agranulocytosis — a severe drop in the number of white blood cells which fight infection — leading to cases of sepsis and five fatalities. Participants in the trial will now have blood cell count monitoring increased from monthly to weekly.  The study has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA).

Tozadenant is an oral adenosine A2a receptor antagonist currently in Phase III development as an adjunctive treatment to levodopa in Parkinson’s disease patients to reduce OFF time.

Statement from the Parkinson’s Foundation

Our thoughts are with the family members who lost a loved one enrolled in this trial. Their participation in clinical research will ultimately help make life better for the people diagnosed with Parkinson's in the future. 

The Parkinson’s Foundation remains confident that Acorda and the FDA will investigate this rare event. Clinical trials in Parkinson’s disease — from oral therapies to surgical treatments — have had a strong safety record and they are critical in testing the safety and efficacy of investigational therapies.

In order to discover new PD therapies, we rely on brave and altruistic people, like the ones in this trial, to participate in clinical research. The Parkinson’s Foundation remains committed to supporting clinical research through our global network of Centers of Excellence and Parkinson’s Advocates in Research.

If you would like more information about the benefits and risks of clinical trial participation, learn more here.  If you have questions or concerns, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636).

Thursday, November 16, 2017
National Parkinson Foundation Hosts Caregiver Summit
Monday, September 12, 2016

MIAMI — The National Parkinson Foundation (NPF), a division of the Parkinson’s Foundation, will be hosting the first-ever Caregiver Summit, geared specifically toward caregivers of people living with Parkinson’s disease (PD).

Refuting Claims Regarding Presidential Nominee Hillary Clinton and Parkinson’s Disease
Friday, September 9, 2016

The National Parkinson Foundation has received several questions about whether Hillary Clinton has Parkinson's disease (PD).

The allegations that Hillary Clinton suffers from Parkinson's disease have been reviewed by NPF's National Medical Director, Michael S. Okun, MD, and by others from NPF's Centers of Excellence network and been unanimously dismissed by every Parkinson's expert who has weighed in.

Parkinson's Disease Foundation Invests in Next Generation of Physical Therapy Leaders
Thursday, August 4, 2016

PDF Launches Innovative Pilot Training Program for Physical Therapy Educators

The Parkinson's Disease Foundation® (PDF®) is pleased to announce the launch of the Physical Therapy Faculty Program to improve care for the nearly one million people in the United States living with Parkinson’s disease. The pilot program launched this week in Boston, MA.

National Parkinson Foundation (NPF) and the Parkinson’s Disease Foundation (PDF) Complete Merger to Form the Parkinson’s Foundation
Monday, August 1, 2016

New York and Miami, August 1, 2016—The Boards of Directors of the National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF) announced today that they have finalized the merger of the two non-profit organizations. The organization will operate as the Parkinson's Foundation with offices in New York City and Miami.

Parkinson’s Disease Foundation Opens $500,000 in Grant Funding, Urges Scientists to Address Key Unmet Needs in Patient Community
Thursday, July 21, 2016

New Awards Fund Translational Patient-Driven Research Projects

Parkinson's Disease Foundation Invests in Next Generation of Patient Leaders
Friday, July 15, 2016

The Parkinson's Disease Foundation® (PDF®) is pleased to welcome 20 people with Parkinson's disease and care partners to its national research advocacy network. These individuals join more than 325 patient leaders who are helping PDF solve, treat and end Parkinson's disease.

The National Parkinson Foundation’s Moving Day® Walks Fund Parkinson’s Programs in Six Cities
Monday, June 27, 2016

MIAMI — The National Parkinson Foundation (NPF) is proud to announce that the 2015 fall walk season of Moving Day®, A Walk for Parkinson’s, has funded nearly $300,000 in mission services to make life better for people living with Parkinson’s and their caregivers in six communities.

NPF and Global Kinetics Corporation Announce the Commencement of a Clinical Trial to Study Impact of Personal KinetiGraph Use in Routine Clinical Care of Patients with Parkinson's Disease
Wednesday, June 22, 2016

A multi-center, randomized controlled trial to assess whether the use of continuous objective measurement of changes in mobility in patients with Parkinson’s disease can improve physician treatment decisions and patient outcomes.

The National Parkinson Foundation Partners with Honor to Help the Home Care Company Deliver Personalized Care in the Home
Tuesday, June 21, 2016

The National Parkinson Foundation (NPF) and Honor home care announced today a collaborative partnership to bring personalized care in the home to people diagnosed with Parkinson’s.  Honor will license the NPF’s proprietary care guidance.

The National Parkinson Foundation Announces New Findings from Largest-Ever Parkinson’s Study of 8,000 Patients Worldwide
Monday, June 20, 2016

Latest Data Point To Improve Patient Care Through Precision Treatment

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.